Ryogo Minamimoto1, Ida Sonni1, Steven Hancock2, Shreyas Vasanawala3, Andreas Loening3, Sanjiv S Gambhir4,5,6, Andrei Iagaru7. 1. Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California. 2. Department of Radiation Oncology, Stanford University, Stanford, California. 3. Radiological Sciences Laboratory, Department of Radiology, Stanford University, Stanford, California. 4. Department of Radiology, Stanford University, Stanford, California. 5. Department of Bioengineering, Stanford University, Stanford, California; and. 6. Department of Materials Science and Engineering, Stanford University, Stanford, California. 7. Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California aiagaru@stanford.edu.
Abstract
68Ga-labeled DOTA-4-amino-1-carboxymethyl-piperidine-d-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 (68Ga-RM2) is a synthetic bombesin receptor antagonist that targets gastrin-releasing peptide receptor (GRPr). GRPr proteins are highly overexpressed in several human tumors, including prostate cancer (PCa). We present data from the use of 68Ga-RM2 in patients with biochemical recurrence (BCR) of PCa and negative findings on conventional imaging. Methods: We enrolled 32 men with BCR of PCa, who were 59-83 y old (mean ± SD, 68.7 ± 6.4 y). Imaging started at 40-69 min (mean, 50.5 ± 6.8 min) after injection of 133.2-151.7 MBq (mean, 140.6 ± 7.4 MBq) of 68Ga-RM2 using a time-of-flight-enabled simultaneous PET/MRI scanner. T1-weighted, T2-weighted, and diffusion-weighted images were acquired. Results: All patients had a rising level of prostate-specific antigen (PSA) (range, 0.3-119.0 ng/mL; mean, 10.1 ± 21.3 ng/mL) and negative findings on conventional imaging (CT or MRI, and a 99mTc-methylene diphosphonate bone scan) before enrollment. The observed 68Ga-RM2 PET detection rate was 71.8%. 68Ga-RM2 PET identified recurrent PCa in 23 of the 32 participants, whereas the simultaneous MRI scan identified findings compatible with recurrent PCa in 11 of the 32 patients. PSA velocity was 0.32 ± 0.59 ng/mL/y (range, 0.04-1.9 ng/mL/y) in patients with negative PET findings and 2.51 ± 2.16 ng/mL/y (range, 0.13-8.68 ng/mL/y) in patients with positive PET findings (P = 0.006). Conclusion: 68Ga-RM2 PET can be used for assessment of GRPr expression in patients with BCR of PCa. High uptake in multiple areas compatible with cancer lesions suggests that 68Ga-RM2 is a promising PET radiopharmaceutical for localization of disease in patients with BCR of PCa and negative findings on conventional imaging.
68Ga-labeled DOTA-4-amino-1-carboxymethyl-piperidine-d-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 (68Ga-RM2) is a synthetic bombesin receptor antagonist that targets gastrin-releasing peptide receptor (GRPr). GRPr proteins are highly overexpressed in several humantumors, including prostate cancer (PCa). We present data from the use of 68Ga-RM2 in patients with biochemical recurrence (BCR) of PCa and negative findings on conventional imaging. Methods: We enrolled 32 men with BCR of PCa, who were 59-83 y old (mean ± SD, 68.7 ± 6.4 y). Imaging started at 40-69 min (mean, 50.5 ± 6.8 min) after injection of 133.2-151.7 MBq (mean, 140.6 ± 7.4 MBq) of 68Ga-RM2 using a time-of-flight-enabled simultaneous PET/MRI scanner. T1-weighted, T2-weighted, and diffusion-weighted images were acquired. Results: All patients had a rising level of prostate-specific antigen (PSA) (range, 0.3-119.0 ng/mL; mean, 10.1 ± 21.3 ng/mL) and negative findings on conventional imaging (CT or MRI, and a 99mTc-methylene diphosphonate bone scan) before enrollment. The observed 68Ga-RM2 PET detection rate was 71.8%. 68Ga-RM2 PET identified recurrent PCa in 23 of the 32 participants, whereas the simultaneous MRI scan identified findings compatible with recurrent PCa in 11 of the 32 patients. PSA velocity was 0.32 ± 0.59 ng/mL/y (range, 0.04-1.9 ng/mL/y) in patients with negative PET findings and 2.51 ± 2.16 ng/mL/y (range, 0.13-8.68 ng/mL/y) in patients with positive PET findings (P = 0.006). Conclusion: 68Ga-RM2 PET can be used for assessment of GRPr expression in patients with BCR of PCa. High uptake in multiple areas compatible with cancer lesions suggests that 68Ga-RM2 is a promising PET radiopharmaceutical for localization of disease in patients with BCR of PCa and negative findings on conventional imaging.
Authors: Thomas A Hope; Zahi A Fayad; Kathryn J Fowler; Dawn Holley; Andrei Iagaru; Alan B McMillan; Patrick Veit-Haiback; Robert J Witte; Greg Zaharchuk; Ciprian Catana Journal: J Nucl Med Date: 2019-05-23 Impact factor: 10.057
Authors: Jens Kurth; Bernd Joachim Krause; Sarah M Schwarzenböck; Carina Bergner; Oliver W Hakenberg; Martin Heuschkel Journal: Eur J Nucl Med Mol Imaging Date: 2019-09-03 Impact factor: 9.236
Authors: Paige M Glumac; Joseph P Gallant; Mariya Shapovalova; Yingming Li; Paari Murugan; Shilpa Gupta; Ilsa M Coleman; Peter S Nelson; Scott M Dehm; Aaron M LeBeau Journal: Clin Cancer Res Date: 2019-11-15 Impact factor: 12.531
Authors: Esther Mena; Peter C Black; Soroush Rais-Bahrami; Michael Gorin; Mohamad Allaf; Peter Choyke Journal: World J Urol Date: 2020-07-15 Impact factor: 4.226